Marker Therapeutics reports Q3 net loss $2.0M; APOLLO study shows 66% ORR, 50% CR in NHL

Marker Therapeutics, Inc.

2025-Q3 EPS reported -$0.75 revenue$2,443,225

Cash $17.6M + restricted $1.4M; runway into Q3 2026; raised ~$10M via ATM.
Net loss $2.0M (improved from $2.3M YoY); R&D $2.3M (down from $3.5M).
APOLLO study: 66% ORR, 50% CR in 12 relapsed NHL patients; durable responses (≥6 months in 5); dose expansion ongoing.
First patient dosed in OTS RAPID study (MT-401) for AML/MDS; cGMP manufacturing pact with Cellipont.
Appointed Kathryn Penkus Corzo to Board; two ASH presentations scheduled Dec 2025.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-25-111940
form_type: 8-K
ticker: MRKR
cik: 0001094038
company_name: Marker Therapeutics, Inc.
filed_at: 2025-11-14T23:59:59+00:00
discovered_at: 2026-05-14T18:02:38.776989+00:00
generated_at: 2026-05-16T19:39:44.554280+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-25-111940
json_url: https://secwatch.observer/filing/0001104659-25-111940.json
markdown_url: https://secwatch.observer/filing/0001104659-25-111940.md
text_url: https://secwatch.observer/filing/0001104659-25-111940.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465925111940/0001104659-25-111940-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1094038/000110465925111940/tm2530894d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-25-111940

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.